Radioisotope imaging developer Molecular Insight Pharmaceuticals has received grants from the U.S. National Institutes of Health for three new research projects, according to the Cambridge, MA-based company.
One award, from the National Institute of Neurological Disorders and Stroke, will fund development of new radiopharmaceuticals to identify changes in dopamine transporters, with potential for diagnosis and monitoring of therapy in Parkinson’s disease, attention deficit-hyperactivity disorder (ADHD), and cocaine addiction.
The second grant, from the Institute of Child Health and Human Development, will build on earlier research in the role of the dopamine D4 receptor in ADHD to identify potential compounds with high affinity for the receptors. Research on these two grants will be conducted at McLean Hospital in Belmont, MA, the company said.
The third award, from the National Institute of Allergy and Infectious Disease, will fund a project designed to develop peptide libraries that incorporate Molecular Insight’s single amino acid chelate chemistry platform as novel imaging probes for visualizing infection. The research will be conducted at Syracuse University in Syracuse, NY.
By AuntMinnie.com staff writers
October 16, 2003
Related Reading
Molecular Insight Pharmaceuticals to start phase III trials, September 15, 2003
Copyright © 2003 AuntMinnie.com
